SCHEMBL2842270

SCHEMBL2842270

CC(C)(C)OC(=O)N1CCC(=O)C(C(=O)CC2CCCC2)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
KMT2A Q03164 1/20 0.44
BACE1 P56817 2/20 0.42
CTSD P07339 1/20 0.42
DDB1 Q16531 1/20 0.42
CRBN Q96SW2 1/20 0.42
GLS O94925 3/20 0.41
FEN1 P39748 1/20 0.41
EPHX1 P07099 1/20 0.40
NR1H2 P55055 1/20 0.40
HPGD P15428 1/20 0.39
KDM1A O60341 1/20 0.39
ACKR3 P25106 1/20 0.38
PDE4B Q07343 1/20 0.38
KDM4E B2RXH2 2/20 0.38
THRB P10828 1/20 0.38
BCHE P06276 1/20 0.37
HTR6 P50406 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8905844 0.90 BACE1 (0.48) MAPTMEN1ALDH1A1KMT2ABACE1
SCHEMBL2447539 0.89 USP2 (0.45) MAPTMEN1ALDH1A1KMT2ADDB1
SCHEMBL18815293 0.84 MAPT (0.42) MAPTMEN1ALDH1A1KMT2ADDB1
SCHEMBL19743146 0.81 ALDH1A1 (0.40) MAPTMEN1ALDH1A1KMT2ADDB1
SCHEMBL2843749 0.80 MAPT (0.41) MAPTMEN1ALDH1A1KMT2ABACE1
SCHEMBL5223609 0.80 USP2 (0.41) MAPTMEN1ALDH1A1KMT2ADDB1
SCHEMBL2123557 0.80 USP2 (0.41) MAPTMEN1ALDH1A1KMT2ADDB1
SCHEMBL2449302 0.80 ITGB3 (0.39) ALDH1A1KMT2AEPHX1HPGDKDM4E
SCHEMBL17868663 0.80 MAPT (0.46) MAPTMEN1ALDH1A1KMT2ADDB1
SCHEMBL14251617 0.79 HPGD (0.43) MAPTMEN1ALDH1A1KMT2ADDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 US disclosed
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 US disclosed
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 US disclosed
CN-102272133-A Modulators of amyloid beta 2011-12-07 CN disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 US disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 US disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 US disclosed
WO-2010053438-A1 MODULATORS OF AMYLOID BETA. ASTRAZENECA AB (SE) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130495-A1 COMPOUNDS 563 BACE1, PSEN1, PSEN2 MAPT 10/4885MEN1 1570/4885ALDH1A1 4124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.